ALPS Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
ALPS Advisors's NBIX Position: Q3 2026 in Review
ALPS Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 3,690 shares worth $523K. The stake represents ﹤0.01% of the portfolio and ranks #991 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in NBIX as recently as Q4 2025.
ALPS Advisors first reported a position in NBIX in Q1 2015 and has held it in 20 quarters since. The position peaked at $6.42M in Q4 2015. 773 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- ALPS Advisors held 3,690 shares of Neurocrine Biosciences worth $523K as of Q3 2026.
- Neurocrine Biosciences was a new ALPS Advisors position in Q3 2026.
- Neurocrine Biosciences made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #991 holding.
- ALPS Advisors first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 20 quarters since.
- ALPS Advisors's Neurocrine Biosciences position peaked at $6.42M in Q4 2015.
- 773 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.